Language notice: the explanatory pages on this website are in English. The source publication and PDF are currently available in Dutch only. We maintain one authoritative PDF to prevent versions from drifting apart.

Caretrap | Stichting Zorgfuik has made Dutch working paper 0.2 of ACNES in Nederland available for reading, download and critical review. It is an exploratory evidence audit of incidence estimates, diagnostic delay, healthcare use, costs, treatment outcomes and possible downstream harm.

Why this document is needed

ACNES (anterior cutaneous nerve entrapment syndrome) is a recognised cause of chronic abdominal wall pain. The Netherlands has a clinical guideline and specialist treatment expertise. Yet there are no current nationwide measurements of the true number of people affected, average time to recognition, or the psychological, occupational and financial consequences of a prolonged pathway.

Core finding:The Netherlands has the clinical knowledge to recognise and treat ACNES, but does not adequately measure how many people are affected or what happens during the pathway.

Evidence remains labelled

Key claims are marked as measured, calculated, association, case signal or unknown. This prevents a precise-looking number from being presented as a nationwide fact when it is a regional estimate, extrapolation or historical cost figure.

Downstream harm cannot simply be dismissed

Longitudinal pain research supports a reciprocal relationship between chronic pain and depression and an association with sickness absence. The average ACNES-specific contribution has not yet been measured well enough.

A lack of ACNES-specific evidence should not be mistaken for evidence that downstream harm does not exist.

One case is a signal, not an average

An anonymised case shows how hospital care, mental healthcare, medication costs and prolonged absence from work may converge in one complex pathway. It is not used to calculate a national average or a causal share attributable to ACNES.

What must happen next

A final version requires independent medical and methodological review, verification of references, privacy review and transparent disclosure of authorship, interests and funding. Corrections and additional primary sources are welcome.

Read the English overview and disclaimersOpen Dutch PDF
Important: working paper 0.2 is not a clinical guideline, personal treatment advice, systematic review or definitive nationwide cost study. New sources and independent review may change its content.